Equillium (EQ) Change in Accured Expenses (2018 - 2026)
Equillium (EQ) reported Change in Accured Expenses of -$257000.0 for Q1 2026, up 67.3% year-over-year from -$153613.7 in Q1 2025, and down 382.42% quarter-over-quarter from $91000.0 in Q4 2025.
Equillium (EQ) Change in Accured Expenses (2018 - 2026) Analysis & Trends
Equillium (EQ) has 9 years of Change in Accured Expenses data on file, last reported at -$257000.0 in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$257000.0, up 67.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.2 million (up 60.67% YoY), and the FY2025 annual result was -$1.7 million, up 46.74% from the prior year.
- Change in Accured Expenses declined to -$257000.0 in Q1 2026 per EQ's latest filing, from $91000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $2.1 million in Q2 2023 and troughed at -$1.9 million in Q3 2024.
- A 5-year average of -$307529.4 and a median of -$475000.0 in 2025 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses sank 453.64% in 2022, then jumped 1018.34% in 2023.
- A 5-year view of Change in Accured Expenses shows it stood at $908000.0 in 2022, then plunged by 288.33% to -$1.7 million in 2023, then advanced by 10.29% to -$1.5 million in 2024, then surged by 105.93% to $91000.0 in 2025, then slumped by 382.42% to -$257000.0 in 2026.
- Business Quant data shows EQ's Change in Accured Expenses at -$257000.0 in Q1 2026, $91000.0 in Q4 2025, and -$475000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - | -257,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -257,000.00 |
| Mar 31, 2026 | -257,000.00 |
| Dec 31, 2025 | 91,000.00 |
| Dec 31, 2025 | 91,000.00 |
| Sep 30, 2025 | -475,000.00 |
| Sep 30, 2025 | -475,000.00 |
| Jun 30, 2025 | -515,000.00 |
| Jun 30, 2025 | -515,000.00 |
| Mar 31, 2025 | -786,000.00 |
| Mar 31, 2025 | -786,000.00 |
| Dec 31, 2024 | -1.53 Mn |
| Dec 31, 2024 | -1.53 Mn |
| Sep 30, 2024 | -1.86 Mn |
| Sep 30, 2024 | -1.86 Mn |
| Jun 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 1.24 Mn |
| Mar 31, 2024 | -1.01 Mn |
| Mar 31, 2024 | -1.01 Mn |
| Dec 31, 2023 | -1.71 Mn |
| Dec 31, 2023 | -1.71 Mn |